ProPhase Labs, Inc.
PRPHOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $6.8M | $35.0M | $122.6M | $79.0M | $14.5M |
| Operating income | −$18.0M | −$38.6M | −$21.2M | $23.6M | $9.8M | −$2.1M |
| Net income | −$14.7M | −$53.4M | −$16.8M | $18.5M | $6.3M | −$2.1M |
| Total assets | $59.9M | $63.2M | $91.9M | $87.6M | $89.3M | $31.4M |
| Total liabilities | $56.4M | $55.8M | $42.5M | $24.0M | $30.7M | $20.8M |
| Equity | $3.5M | $7.4M | $49.4M | $63.6M | $58.6M | $10.6M |
| EPS (diluted) | $-1.74 | $-26.68 | $-0.98 | $1.02 | $0.40 | $-0.18 |
| Shares out. | 41.9M | 18.0M | 17.2M | 15.5M | 15.2M | 11.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −415.4%
- Net margin
- −339.3%
- Return on equity
- −420.3%
- Return on assets
- −24.6%
- Return on capital (ROCE)
- −265.8%
- Liabilities / assets
- 94.1%
- Debt / equity
- 16.07×
- Book value / share
- $0.08
- Revenue growth (YoY)
- −35.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -11.41distress
- Accruals / assets
- −10.7%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 27, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2025
- NT 10-Qmissed a reporting deadline ↗May 16, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 67,595 | 1.0 | +6.4% |
| Apr 30, 2026 | 63,551 | 1.0 | +44.0% |
| Apr 15, 2026 | 44,129 | 1.0 | -0.4% |
| Mar 31, 2026 | 44,294 | 1.0 | -36.5% |
| Mar 13, 2026 | 69,774 | 1.0 | +12.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventFeb 13, 2026
- Other material eventFeb 13, 2026
- Other material eventJan 27, 2026
- Other material eventJan 23, 2026
- Entered a material agreement · Unregistered equity saleJan 23, 2026
- Other material eventJan 9, 2026
- Director / officer changeJan 9, 2026
- Delisting / listing-standard noticeJan 2, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.